Evidence map›Paper›PMID 35007776›Full record

ArticleJournal of gynecology obstetrics and human reproduction2022

The psychological impact of therapeutic changes during the COVID-19-lockdown for gynaecological and breast cancer patients

G Lamblin, G Chene, E Leaune, C A Philip, S Moret, E Nohuz, F Golfier, M Cortet

Open access · bronzeAbstract readMulticenter Study
In one paragraph

Article in Journal of gynecology obstetrics and human reproduction, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

G LamblinDepartment of Obstetrics and Gynaecology Surgery, Femme Mère Enfant University Hospital, Hospices Civils de Lyon, Bron, France; University of Lyon, Université Claude Bernard Lyon 1, Lyon, France. Electronic address: gery.lamblin@chu-lyon.fr.
G CheneDepartment of Obstetrics and Gynaecology Surgery, Femme Mère Enfant University Hospital, Hospices Civils de Lyon, Bron, France; University of Lyon, Université Claude Bernard Lyon 1, Lyon, France.
E LeauneCentre de Prévention du Suicide, Centre Hospitalier le Vinatier, 69500 Bron, France.
C A PhilipDepartment of Obstetrics and Gynaecology Surgery, Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France.
S MoretDepartment of Obstetrics and Gynaecology Surgery, Femme Mère Enfant University Hospital, Hospices Civils de Lyon, Bron, France.
E NohuzDepartment of Obstetrics and Gynaecology Surgery, Femme Mère Enfant University Hospital, Hospices Civils de Lyon, Bron, France; University of Lyon, Université Claude Bernard Lyon 1, Lyon, France.
F GolfierDepartment of Obstetrics and Gynaecology Surgery, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, 165 chemin du Grand Revoyet, 69310 Pierre Bénite, France.
M CortetDepartment of Obstetrics and Gynaecology Surgery, Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France; LabTAU, Unité INSERM U 1032, Université Claude Bernard Lyon 1, Lyon, France.
Hospices Civils de Lyon · FRCentre Hospitalier Le Vinatier · FRHôpital de la Croix-Rousse · FRUniversité Claude Bernard Lyon 1 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe exceptional health situation related to the Coronavirus 2019 (COVID-19) pandemic has required an in-depth and immediate reorganisation of gynaecological cancer care. The main objective was to assess the psychological impact of such treatment modifications during the lockdown period for gynaecological and breast cancer patients. PATIENTS AND

methodsA multicentre prospective study was conducted in three university gynaecological cancer wards (Hospices Civils de Lyon, France) during the French first lockdown (16th March to 11th May 2020). All patients with non-metastatic breast cancer or gynaecological cancer were included. Data was collected regarding treatment modifications (delay, cancellation, change of therapeutic plan). The psychological impact of treatment modifications during and after the lockdown was assessed by validated questionnaires (SF-12, EORTC-QLQ-C30, HADS).

resultsA total of 205 consecutive patients were included, aged 60.5 ± 1.0 years. Seven patients (3.4%) presented a SARS-CoV-2 infection, and two patients died. Treatment was maintained for 122 (59.5%) patients, postponed for 72 (35.1%) and cancelled for 11 (5.4%). During the lockdown, 35/118 (29.7%) patients suffered from confirmed anxiety and the mean fatigue-EORTC score was 48.00 ± 2.51; it was 38.64 ± 2.33 (p = 0.02) after the lockdown. After the lockdown and compared to the lockdown period, the mental SF-12 score and overall health status EORTC score were significantly higher (45.03 ± 1.06 vs 41.71 ± 1.15, p = 0.02 and 64.58 ± 1.66 vs 57.44 ± 2.02, p = 0.0007, respectively). The number of confirmed-anxiety cases was significantly higher amongst patients for whom treatment was delayed or cancelled (40.5% vs 23.7%, p = 0.04).

conclusionThis study quantified the treatment modifications of gynaecological cancer patients during the COVID-19 lockdown and revealed a poorer psychological state and quality of life during this period, even for patients whose treatment plan was not actually modified. Anxiety was more significant in patients with a delayed or cancelled treatment.

Indexed as

Breast NeoplasmsCOVID-19Communicable Disease ControlFemaleHumansMiddle AgedProspective StudiesQuality of LifeSARS-CoV-2breast cancerCOVID-19 pandemicGynaecological cancerPsychological symptomsSARS-CoV-2

Identifiers

PMID35007776
PMCPMC8739811
OpenAlexW4220967187

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.